Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (EBV-LPD) results from the outgrowth of EBVinfected B cells that would normally be controlled by an effective EBV-specific cytotoxic T-cell (CTL) response.
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EBV-LPD occurs after allo-SCT as an EBV-associated post transplantation lymphoproliferative disorder (EBV-PTLD), with an overall incidence of B1% and a mortality rate as high as 50-90%. [2] [3] [4] Almost all cases of EBV-PTLD develop within the first year of transplantation before reconstitution of EBV-specific CTL response; however, it occurs later in the most severely immunocompromised patients, and extensive chronic GVHD is the only risk factor for lateonset EBV-PTLD. 2 Recently, the survival of patients with EBV-PTLD has been improved by combination chemotherapy with rituximab and donor lymphocyte infusions (DLI). 5, 6 Fulminant EBV-LPD is another type of fatal EBV-associated disease, which is caused by the proliferation of EBV-infected T cells. Here, we report an unusual case of fulminant EBV-LPD with meningoencephalitis that developed 14 years after unrelated BMT. Furthermore, EBV-infected B and T cells were successfully eliminated by rituximab and DLI.
The patient was a 52-year-old male with ALL (L2) who underwent unrelated BMT in February 1995 at the age of 38 years. The conditioning regimen consisted of BU 12 mg/kg, CY 120 mg/kg and etoposide (VP-16) 60 mg/kg. CsA and short-term MTX were given for GVHD prophylaxis. The patient developed grade II acute GVHD that was controlled with 2 mg/kg prednisolone. Eventually CsA was discontinued in October 1995. The patient had been well for 13 years without relapse or chronic GVHD until September 2009 when he suddenly developed persistent fever, delirium, hepatorenal dysfunction, thrombocytopenia, massive pleural effusion and ascites. These symptoms rapidly progressed; he was admitted to the intensive care unit and plasma exchange was immediately started on the basis of a tentative diagnosis of thrombotic thrombocytopenic purpura without any improvement. Computed tomography scan showed massive pleural and peritoneal effusion, but lymphadenopathy or hepatosplenomegaly were not seen. The EBV serology pattern indicated a previous EBV infection, and a high level of EBV DNA (2.0 Â 10 5 copies per ml) was detected in the blood. Cytology and flow cytometry of pleural effusion showed CD8 þ T-cell infiltration, and DNA from the pleural effusion was EBV positive. Although brain computed tomography and magnetic resonance imaging were normal, cerebrospinal fluid examination showed increased mononuclear cells (MNCs); EBV DNA was also detected in cerebrospinal fluid by PCR. Detection of EBV-encoded RNA by in situ hybridization analysis of BM cells revealed that EBV-encoded RNA-positive T lymphocytes had infiltrated the BM (Figure 1a ). The clonality analysis of EBV-infected cells by Southern blot, with a probe targeting EBV terminal repeats, indicated oligoclonal populations of EBV (Figure 1b ). On the basis of these findings, the diagnosis of very-late-onset EBV-LPD with meningoencephalitis was made; chemotherapy with VP-16 followed by CHOP regimen (CY, 750 mg/m 2 on day 1; adriamycin, 50 mg/m 2 on day 1; VCR, 1.4 mg/m 2 on day 1; prednisolone, 100 mg on days 1-5) was given with transient minimal response.
Flow cytometry of the PBL fractions, which were separated using antibodies conjugated with magnetic beads (IMag cell separation system, BD Biosciences, Franklin Lakes, NJ, USA) 7 after chemotherapy, revealed that the remaining EBV-infected cells were mainly B cells and that a small fraction of gdT cells were also present (Figure 2A ). Then, rituximab was administered at a dose of 375 mg/m 2 weekly (four doses were administered) to eliminate EBV-infected B cells. With this treatment, the patients' general condition was slightly improved, but he remained in a serious condition with impaired mental status, with symptoms such as disorientation, agitation and delirium. Although 14 years had passed since transplantation, we were able to contact the donor through Japan Marrow Donor Program. MNCs from 200 mL of whole blood from the donor were infused with the informed consent. With these treatments, EBV-specific CTL responses were induced and both EBV-infected B and T cells were eliminated from the blood (Figure 2A) . Eventually, DNA became EBV negative in the peripheral blood and cerebrospinal fluid ( Figure 2B ). The patient's mental status dramatically improved and he was discharged from the hospital.
The present case has unusual characteristics and features that are different from typical cases of EBV-PTLD in many ways: disease onset, symptoms, severity, immune status and the type of proliferative EBV-infected cells. The patient had developed EBV-LPD 14 years after unrelated BMT; he had been free of chronic GVHD and immunosuppressive drugs for most of this time. The typical pattern of EBV-infected B-cell proliferation was not seen, but the case showed EBV-infected T-cell as well as B-cell proliferation. Quintanilla-Martinez et al. reported six cases of fulminant T-cell EBV-LPD that progressed to multiple organ failure, sepsis and death after initial or chronic infection of EBV. 8 The symptoms and pathogenesis of the patient were more consistent with fulminant T-cell EBV-LPD than typical EBV-PTLD, although there was no report of fulminant EBV-LPD following transplantation.
The prognosis of fulminant EBV-LPD tends to be poor. However, we could save the patient with rituximab and DLI. This treatment strategy was enabled by the close peripheral blood B cells, T cells and activated CD8 þ T cells separated by antibodies conjugated with magnetic beads after the administration of rituximab before (top) and after (bottom) DLI. The remaining gdT cell fractions after rituximab treatment were dramatically decreased after DLI and activated CD8 þ , HLA-DR þ T cell fractions were increased after DLI (f). (g, h) EBV-specific CTL responses were induced after DLI. HLA-A0201 restricted phycoerythrin-conjugated EBV tetramer mix (LMP2, BRLF1, BMLF1, EBNA3A, EBNA3B; Medical and Biological Laboratories, Nagoya, Japan) was pulsed and analyzed by flow cytometry. EBV-specific CD8 þ CTL responses were negative before DLI (g), but were found in 2.2% of MNC fractions after DLI (h). (B) Amount of EBV DNA in plasma, whole blood cells and peripheral B and gdT cells before rituximab (a), 3 weeks (b) and 6 weeks (c) after DLI. After rituximab therapy, EBV DNA in B cells became negative. EBV DNA was detected in plasma, whole blood cells and in gdT cells 3 weeks after DLI, but was completely eliminated 6 weeks after DLI. EBV DNA in plasma: copies per ml; EBV DNA in whole blood cells, B cells and T cells: copies per mg DNA.
monitoring of the EBV-infected lymphocyte fractions and EBV copy numbers. We confirmed that EBV-infected B cells were eliminated following rituximab administration; in addition, the remaining gdT cells were eliminated with the subsequent DLI by inducing EBV-specific CTL responses. In addition, EBV-infected cells infiltrating the central nervous system were evidently eliminated by DLI. EBV-LPD with central nervous system involvement is rarely cured with rituximab, because rituximab does not cross the blood-brain barrier very well and its concentration in cerebrospinal fluid following i.v. administration is not in the therapeutic range. 9, 10 The only potentially effective treatment for the central nervous system disease is to generate or infuse EBV-specific CTLs. 11 Fortunately, we could find the original donor 14 years after transplantation and allogeneic EBV-specific CTLs were successfully induced; however, finding the original donor in a timely manner after BMT is not always feasible in most cases. Haque et al. 12 reported the results of a phase II multicenter clinical trial for refractory EBV-PTLD using EBV-specific CTLs generated from EBV-seropositive, partly HLAmatched, unrelated donors. In their report, the response rate at 6 months was 52%. If the original donor is not available, banked, third party, EBV-specific CTL infusion might be a treatment option for EBV-PTLD patients with central nervous system disease. In summary, rituximab followed by DLI induced durable remission through the induction of EBV-specific CTL responses and enabled the elimination of EBV-infected cells in patients with fulminant EBV-LPD even 14 years after allo-SCT. This is the first case to indicate the efficacy of DLI for treating EBV-LPD developed during the long-term interval since the transplant. Close monitoring of EBVinfected cells was useful to develop treatment strategies. Because of the increasing number of long-term allo-SCT survivors, the incidence of late-onset EBV-LPD may increase and our experience provides useful information to treat this disease.
